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ABSTRACT
Objectives A collaborative service initiative involving 
community pharmacists and a specialist mental health 
pharmacist was developed to provide pharmacist reviews 
for care home residents with intellectual disabilities (IDs). 
This study aimed to characterise the medicines and 
lifestyle risk outcomes of the service and determine how 
these align with national priority issues in ID.
Design Descriptive statistical analysis of routinely 
collected service delivery data.
Setting Residential care homes in the Wirral, England for 
people with ID.
Participants 160 residents.
Interventions Pharmacist review of residents’ medicines 
and lifestyle risk factors between November 2019 and May 
2020.
Primary and secondary outcome measures Numbers 
of medicines prescribed, the nature of pharmacists’ 
interventions/recommendations and general practitioner 
(GP)/psychiatrist acceptance.
Results The 160 residents were prescribed 1207 
medicines, 74% were prescribed ≥5 medicines and 507 
interventions/recommendations were made, averaging 3.3 
per resident. The highest proportion (30.4%) were lifestyle 
risk related, while changing and stopping medicines 
accounted for 17.9% and 12.8%, respectively. Of the 
recommendations discussed with GPs/psychiatrists, 
86% were accepted. Medicines with anticholinergic 
properties were prescribed for 115 (72%) residents, of 
whom 43 (37%) had a high anticholinergic burden score. 
Pharmacists recommended anticholinergic discontinuation 
or dose reduction for 28 (24%) residents. The pharmacists 
made interventions/recommendations about constipation 
management for 10% of residents and about respiratory 
medicines for 17 (81%) of the 21 residents with 
respiratory diagnoses.
Conclusions The findings indicate considerable 
polypharmacy among the residents and a high level 
of pharmacists’ interventions/recommendations about 
medicines and lifestyle risk, most of which were accepted 
by GPs/psychiatrists. This included anticholinergic 
burden reduction and improving respiratory disease and 
constipation management, which are national priority 
issues. Wider adoption of collaborative pharmacist 
review models could have similar benefits for residential 
populations with ID and potentially reduce pressure on 
other health services.
INTRODUCTION
An intellectual disability (ID) is defined 
as a ‘reduced intellectual ability and diffi-
culty with everyday activities which affects 
someone for their whole life’.1 People with 
ID often have complex care needs, with an 
increased likelihood of premature death.2 
This was highlighted in The Learning Disability 
Mortality Review (LeDeR) Annual Report 
2018,3 which described a disparity in the age 
of death for people with ID, compared with 
the general population. The Wirral Joint 
Strategic Needs Assessment cites individuals 
with ID are possibly twice as likely to have 
asthma, 25 times more likely to have epilepsy 
and have higher levels of mental health 
problems.4 Nationally, the National Health 
Service (NHS) Long Term Plan (2019) 
commits to ensuring people with ID get 
Strengths and limitations of this study
 ► This is the first study to evaluate a novel collabora-
tive pharmacy service model, including both com-
munity and specialist mental health pharmacists in 
intellectual disability residential care.
 ► This study uses routinely collected data that 
make both the study and future work amenable to 
replication.
 ► The study findings relate to one geographical area 
in England only.
 ► Pharmacists had limited access to residents’ health-
care records; greater access may have reduced or 
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better support and to improve the use of psychotropic 
medication with the nationally established programme 
Stopping the Over- Medication of People with Learning Disabil-
ities (STOMP).5 6
Within care homes for older people, pharmacist input 
is known to improve patient outcomes by improving medi-
cines administration accuracy and efficiency and reducing 
adverse effects of medicines and medicines adminis-
tration errors.7 In particular, patient care is improved 
through exploration of practical medicines issues such 
as formulation and dose timing.7 More broadly, pharma-
cist interventions in care homes can improve clinically 
significant outcomes, such as the number of falls,8 depre-
scribing or identifying safety issues.9 Using tools such as 
STOP- START, studies have demonstrated reductions in 
polypharmacy, optimisation of patient medicines and cost 
savings.10
Despite the similarity of the setting, there is little 
evidence of the impact of pharmacist interventions in 
residential care for people with ID, where medicines are 
also administered. One small- scale study reported that a 
high number of interventions were made when a phar-
macist conducted medicines reviews with people with 
ID, of which over 40% concerned the ordering of repeat 
prescription medicines.11 However, limited detail about 
these interventions was provided and so determining the 
pharmaceutical needs of people with ID largely remains 
a matter of assumption based on known poorer health 
outcomes.12 These assumptions include overprescribing 
of antipsychotics,5 that medicines side effects are not 
well recognised or managed,13 polypharmacy (more 
pronounced in residential institutions)14 and other issues 
that affect the population at large such as lifestyle risk 
factors and suboptimal medicines adherence.
The NHS England work stream—Medicines Optimisation 
in Care Homes15—facilitates and funds pharmacists, based 
in primary care, to conduct medicines reviews in care 
homes. In the Wirral, conducting pharmacist reviews for 
ID care home residents was identified as a gap by the Clin-
ical Commissioning Group (CCG), in line with the NHS 
Long Term Plan (2019).6 Furthermore, data provided by 
Wirral CCG showed variation in prescribing trends, with 
the average number of medicines per ID resident varying 
from 0 to more than 11 across different residential loca-
tions. A similar variation was seen in the prescribing of 
antipsychotics, antidepressants and sedatives. To make 
best use of local pharmacist resource, a cross- sector, 
collaborative initiative was designed to coordinate the 
reviews between community and specialist mental health 
pharmacists. This involved pharmacists from community 
pharmacies (both independent and large company) and 
the local Specialist Mental Health NHS Foundation Trust.
This initiative was commissioned by Wirral CCG to 
provide a combination of pharmacist reviews and care 
home wastage audits. The evaluation of the service initia-
tive presented here relates to the pharmacist reviews, and 
the aim of the evaluation was to characterise the medi-
cines and public health outcomes of the collaborative 
pharmacist review service for residents with ID and deter-
mine how these align with the LeDeR report priorities.3
METHODS
Description of the service initiative intervention
The collaborative pharmacist review service initiative 
involved pharmacists reviewing ID care home residents’ 
medicines using a structured review framework and where 
applicable making interventions or recommendations to 
the resident’s general practitioner (GP) and/or psychia-
trist. The framework for the reviews was devised jointly by 
the lead consultant psychiatrist, the strategic lead phar-
macist from the Mental Health Trust and the Local Phar-
maceutical Committee (LPC) representatives to align 
with the 2018 LeDeR report3 priorities. This report was 
central to determining the predicted pharmaceutical 
care gap in this population because many of the areas for 
improvement in care link directly to the use or under-
standing of medicines by patients or carers. The frame-
work guided the pharmacists through consultations, 
ensuring capture of basic information, before focusing on 
the key recommendations of the LeDeR report.3 These 
included medicines adherence and burden (particularly 
the anticholinergic burden), respiratory care, vaccina-
tion status, constipation risk, sepsis prevention, dysphagia 
risk and lifestyle risk issues, especially smoking. Finally, 
pharmacists were asked to detail actions taken/advice 
provided, any recommendations made and make refer-
rals, as necessary.
Representatives from the Specialist Mental Health Trust 
and the LPC provided oversight of the initiative, which 
included developing an implementation plan with the 
pharmacists who conducted the reviews and providing 
updates to the commissioner and the Specialist Mental 
Health Trust, in line with the governance frameworks. 
Using anonymised, aggregated data (at ID care home 
level of analysis) provided by Wirral CCG, the oversight 
group separated the ID care homes into two groups 
based on the number of psychotropic medicines known 
to be prescribed to residents. Pharmacists were aligned 
to care homes based on anticipated patient need, psycho-
tropic medicine use and existing care relationships estab-
lished through local medicines supply. Those homes 
with residents with few or no psychotropic medicines 
tended to be assigned to community pharmacists. Those 
with higher psychotropic use tended to be assigned to 
the specialist mental health pharmacist who, as part of 
the review, focused on the resident’s psychotropic care, 
comparing care plans from the resident’s GP and consul-
tant psychiatrist.
The pharmacists then contacted their assigned care 
homes directly and arranged opportunities to visit and 
review residents’ medicines. Residential homes varied in 
size and number of residents, but the maximum occu-
pancy varied from 2 to 29 residents. On arrival, the care 
homes’ prescription ordering, medicines storage and 
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any wastage (and opportunities to reduce) were noted. 
Subsequently, each resident was asked for consent to a 
medicines review, unless advised by the staff that this was 
not in the resident’s best interests, in which case a paper 
review (eg, Medicines Administration Records, home 
notes, etc) was undertaken instead. Where it was found 
that a resident had no capacity to consent, and there 
were no notes detailing a previous assessment, pharma-
cists were asked to establish a best interest decision in line 
with General Pharmaceutical Council guidelines and the 
Mental Capacity Act 2005.
Pharmacists used individual residents’ care home 
records to conduct the reviews. The specialist mental 
health pharmacist also had access to the care record held 
by the Specialist Mental Health Trust, if the resident was 
under the Trust’s care and remote access to the local data 
sharing platform. This provides clinicians outside the 
GP surgery access to limited clinical patient data, such as 
recent blood tests, physical health monitoring (eg, blood 
pressure) and medicines prescribed by the GP. Any urgent 
queries or concerns to a resident’s immediate health were 
discussed with their GP via telephone, querying current 
treatment and requesting input or action as appropriate. 
Where appropriate, the community pharmacists followed 
the service initiative pathway to triage residents to the 
specialist mental health pharmacist and/or their GP. 
Where appropriate, the specialist mental health phar-
macist discussed the resident’s care with the consultant 
psychiatrist.
Several assessments were made, dependent on the 
resident’s medicines history. These included a modified 
Glasgow Antipsychotic Side- effect Scale (GASS) and the 
online tool Medichec (used to measure the anticholin-
ergic burden), currently used within the Trust’s normal 
practice. Additionally, the validated Medication Adher-
ence Report Scale (MAR-5)16 and the COPD Assessment 
Test (CAT)/Asthma Control Test (ACT), frequently used 
within community pharmacy practice to assess medicine 
use. Questions were also asked to confirm the resident’s 
influenza/pneumococcal vaccination and smoking status. 
Wherever possible, the pharmacists also advised on and 
influenced the resident’s general health and lifestyle risk 
factors, such as by making referrals to local smoking cessa-
tion services, with agreement to do so in the review. Other 
examples of lifestyle factors included diet and/or consti-
pation risk and management, alcohol, managing blood 
pressure and exercise, vaccination information and advice 
on the use of supplements or non- prescribed medication.
Following the review, GP surgeries and psychiatrists 
were contacted by the pharmacists to arrange a review 
of their recommendations. As the pharmacists were 
not prescribers, decisions on accepting recommenda-
tions were made by the resident’s GP/psychiatrist (after 
reviewing the resident’s full clinical record) in consulta-
tion with the pharmacists. Any changes to the resident’s 
repeat medicines were made, requests for blood tests or 
referrals completed and a record of the review recorded 
on the GP system.
Details of each review and the outcomes of pharma-
cists’ recommendations were also recorded electronically 
on PharmOutcomes, a web- based secure clinical service 
recording platform, commonly used within community 
pharmacy. The outcomes were categorised by the phar-
macist at the point of data entry. The individual pharma-
cists coordinated their own interventions, ensuring that 
all outcomes were recorded and followed up with the resi-
dent’s GP. Regular telephone conference calls between 
the pharmacists, consultant psychiatrist and the oversight 
group provided a forum to share learnings and high-
light possible trends. This also provided a link between 
the pharmacists and the lead consultant psychiatrist to 
discuss in depth the care of individual residents.
Data collection and analysis
Following institutional ethical approval, an evaluation of 
the data that were routinely collected by the pharmacists 
as part of delivering the service was undertaken. This 
involved downloading data from PharmOutcomes into 
Microsoft Excel and removing all personally identifiable 
data. The outcome categories recorded by the pharma-
cists were ratified by the author NT, based on the free 
text within the consultation record. The data were then 
transferred to IBM SPSS Statistics V.24 and subjected to 
descriptive statistical analysis.
The analysis included identifying and thematically 
grouping the pharmaceutical care needs of the ID resi-
dent population in the study as determined by the inter-
ventions/recommendations made by the pharmacists. 
The data were also assessed against the LeDeR report3 
priorities of medicine adherence and burden, respiratory 
care, vaccination status, constipation risk, sepsis preven-
tion and dysphagia risk.
Patient and public involvement
The study design and outcome measures were informed 
by national priorities,3 which were based on observed 
health outcomes and the priorities and experiences of 
people with ID and those who care for them. The study 
involved routinely collected data that directly concerned 
these national priorities, and as such, the study was also 
based on the priorities and experiences of people with 
ID.
RESULTS
A total of 160 residents received reviews by pharmacists 
(76 by community pharmacists and 84 by the specialist 
mental health pharmacist) between November 2019 and 
May 2020. The advent of the COVID-19 pandemic meant 
that the service was paused prematurely. The mean age of 
the cohort was 56 (SD 13.43), ranging from 24 to 79. Of 
the 160 residents, 31% were reported as female and 69% 
as male.
The analysis of the data is presented with the charac-
terisation of the nature and number of pharmacists’ 
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by an analysis of whether the pharmacists’ interventions/
recommendations were accepted by the resident’s GP 
or psychiatrist. The analyses of the pharmacists’ inter-
ventions and recommendations according to the LeDeR 
report3 priorities are presented last.
Analysis of pharmacists’ interventions/recommendations
There were a total of 507 interventions or recommenda-
tions made by the pharmacists, averaging 3.3 per resident 
(median 3.0, SD 1.97). Table 1 shows a breakdown of the 
interventions and recommendations made by type and 
the number of residents for whom the pharmacists made 
at least one intervention or recommendation of that type. 
In some reviews where multiple medicines required the 
same recommendation or intervention, the pharmacist 
made the same intervention/recommendation more 
than once (eg, recommendations to stop medication or 
change to improve adherence).
Table 1 also shows that most interventions concerned 
changes to residents’ medicines regimes. There was a total 
of 65 evidence- based recommendations made for 49 resi-
dents to stop (or query and potentially stop) medicines, 
the most common of which were folic acid (8), procycli-
dine (7), proton pump inhibitors (7) and antipsychotics 
(5). In addition, there were 23 residents for whom the 
pharmacist recommended that a medicine be started 
(and 25 individual recommendations), the most common 
of which concerned laxatives (7), statins (4), vitamin D 
(2) and bisphosphonates (2).
The pharmacists also commonly made lifestyle risk 
related interventions and recommendations. For 
example, of the 157 residents who had their smoking 
status recorded, 46 (29.3%) were current smokers and 7 
of these agreed to a referral to the local smoking cessation 
services. Fourteen (9%) residents received further infor-
mation to manage their blood pressure, 3 (2%) received 
advice on alcohol consumption and 44 (28%) received 
additional dietary advice and/or advice on managing 
constipation.
Acceptance of pharmacists’ interventions and 
recommendations
Following identification of where interventions were 
needed, including those requiring prompt attention, the 
pharmacists discussed their recommendations with the 
resident’s GP/psychiatrist. The recommendations were 
reviewed and actioned where agreement was reached. 
Interventions already actioned by the pharmacist directly 
(most usually related to lifestyle risk, medicines use or 
adherence advice) were shared with the GP for infor-
mation only. The onset of the COVID-19 pandemic 
paused the project without any certainty of continuation. 
Changing guidance and focusing on essential activities 
across the NHS meant that the pharmacists were not able 
to discuss all their recommendations for some residents 
with the GP.
Of the 160 residents consulted by pharmacists, 168 
interventions/recommendations (for 136 residents) were 
discussed with the GP/psychiatrist. Of these 168 interven-
tions, 144 (86%) were accepted and actioned, while 24 
(14%) were not. Reasons for why GPs did not agree with 
pharmacists’ recommendations were lost to follow- up in 
some instances due to the COVID-19 pandemic, which 
precluded further analysis. A summary of the recom-
mendations discussed with GPs/psychiatrist is shown in 
table 2.
Analysis of medicines adherence and burden
The 160 residents were prescribed a total of 1207 medicines, 
74% of residents were prescribed five or more medicines 
(ie, polypharmacy17), the median number of medicines per 
resident was seven and the range was 0–20 medicines. All 
residents had their medication adherence assessed, using 
the MAR-5, a primarily self- assessment questionnaire vali-
dated across a range of health conditions.16 The number 
of residents who reported their adherence to be 25 out of 
25 was 126 (79%), which broadly tallied with the 25 (16%) 
consultations where the pharmacist made interventions/
recommendations linked directly to suboptimal medicines 
adherence.
In their reviews, the pharmacists identified that 115 resi-
dents (72%) were prescribed medicines with anticholinergic 
Table 1 Number of pharmacists’ interventions or 
recommendations identified by type and by number of 
the 160 residents for whom at least one intervention/






Number of unique 
residents (%)
Adherence (immediate 
change/advice provided to 
improve)
25 (4.9) 22 (13.8)
Lifestyle risk related 
(including referral for 
smoking cessation)
154 (30.4) 89 (55.6)
Recommendation – 
change to medication 
(form/dose/quantity)
91 (17.9) 75 (46.9)
Recommendation – start 
medication
25 (4.9) 23 (14.4)
Recommendation – stop 
medication or query 
medication and stop if no 
rationale
65 (12.8) 49 (30.6)
Referred for later blood 
pressure review
11 (2.2) 11 (6.9)
Referred onwards 42 (8.3) 33 (20.6)
Requests for blood 
monitoring
43 (8.5) 36 (22.5)
Side effects identified 
and advice provided to 
manage
12 (2.4) 12 (7.5)
Update records 12 (2.4) 12 (7.5)
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properties, of which the most commonly prescribed were 
procyclidine, clozapine, olanzapine, carbamazepine and 
diazepam. The Medichec online tool was used to calculate 
the anticholinergic burden for each resident,18 which is 
summarised in figure 1, and shows that the scores ranged 
from 0 to 11, with the mean being 3.3 (SD 2.2). Residents 
with anticholinergic burden scores higher than 3 were 
either identified and directly reviewed by or referred to the 
specialist mental health pharmacist following the service 
initiative pathway and 43 (37%) residents had scores 
warranting such referral and review. Of all the residents 
prescribed medicines with anticholinergic activity (115), 
it was recommended that medicines with anticholinergic 
properties be stopped or the dose be reduced for 28 (24%) 
residents.
The pharmacists assessed residents’ antipsychotic medi-
cines using the GASS19 and two of the residents reported a 
score of 22–42 (moderate side effects), while 89 residents 
reported a score under 21 (absent/mild side effects). None 
of the residents reported a score of 43–63 (severe side 
effects).
Analysis of respiratory care and vaccination status
Twenty- two of the residents required measurements of 
their respiratory health as part of the pharmacist’s review, 
of whom 7 (4%) had received ACT and 15 (9%) received a 
CAT. Of these residents, 14 (64%) were identified as having 
room to improve their respiratory control. The ACT scores 
were broken down as: score of 25 asthma under control 
(one resident), scored 20–24 reasonably well controlled 
(three residents) and under 20 not controlled (three resi-
dents). For the CAT test, three residents scored a CAT score 
above 20 (‘significant room for improvement’), 5 scored 
10–20 (‘room for improvement’) and 7 scored under 10 
(‘COPD has low impact on health’).
Through self- identification or care home records, 22 resi-
dents were identified as being diagnosed as having COPD or 
asthma and 21 (13% of all the residents) were prescribed a 
respiratory medicine (ie, an inhaler or montelukast). These 
residents were prescribed a mean of 2.1 medicines per resi-
dent and a range of 1–5 medicines. The pharmacists made 
interventions/recommendations for 17 of the 21 (81%) 
residents about their prescribed respiratory medication or 
their respiratory diagnosis, including medicine formula-
tion or dose changes (two residents), stopping or starting 
a medicine (two residents), attempts to improve adherence 
(six residents) and referral to the GP (five residents).
In relation to influenza vaccination status, 116 (73%) of 
the residents had been vaccinated, 3 residents (2%) had 
declined vaccination, but of the remaining 41 residents, 25 
(16%) had not been vaccinated and 16 (10%) were unsure 
of their vaccination status. Where residents’ vaccination 
status could not be confirmed, this meant that the resident 
was unaware of being vaccinated, no record of vaccina-
tion administration could be found by the pharmacist or 
the care home and the care home were unable to confirm 
whether the resident had been vaccinated.
Analysis of the risks of constipation, sepsis and dysphagia
A total of 55 (34%) residents were prescribed a laxative. For 
10 of these residents, the pharmacist had recommended 
a change to the timing of doses or choice of laxative to 
improve efficacy, or a change aimed at improving adher-
ence, such as changing to a formulation with a different 
flavour. In addition, the pharmacists recommended that 
seven residents be started on a laxative. As such, the pharma-
cists needed to make an intervention or recommendation 
for approximately 10% of the residents about constipation 
management.
Table 2 Summary of the acceptance of pharmacists’ 











change to medication 
(form/dose/quantity*)
51 (89) 6 (11) 57
Recommendation – start 
medication
15 (68) 7 (32) 22
Recommendation – stop 
medication or query 
medication and stop if no 
rationale
32 (86) 5 (14) 37
Requests for blood 
monitoring
15 (100) 0 (0) 15
Medicines adverse 
effects or clinical 
complications identified
10 (83) 2 (17) 12
Other 21 (84) 4 (16) 25
Total 144 (86) 24 (14) 168
*Recommended changes to regular repeat prescription 
medicine quantities to allow easier management of 
medication by care home/resident.
GP, general practitioner.
Figure 1 Summary of the anticholinergic burden scores 
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None of the residents who were reviewed by the pharma-
cists were identified as having signs or symptoms of sepsis. 
However, two residential homes were provided with addi-
tional written material to provide information to the staff 
about the signs and symptoms of sepsis.
In relation to the risk of dysphagia, four residents 
reported difficulties taking their medication due to possible 
swallowing difficulties, and the pharmacist recommended 
changes to alternative formulations. Conversely, six resi-
dents were prescribed liquid formulations when there was 
no recorded or known rationale or improvement in adher-
ence and alternate formulations were recommended.
DISCUSSION
This study found a high level of polypharmacy among 
residents with ID (three- quarters of residents were 
taking five or more medicines). Through this service 
initiative, the pharmacists identified a high number of 
interventions/recommendations (a median of 3 per 
resident) that were needed to improve residents’ treat-
ment, of which 86% were accepted by the residents’ 
GP/psychiatrist. Previous reports have already estab-
lished that people with ID have higher pharmaceutical 
care needs due to multimorbidity and polypharmacy11 
and a corresponding reduced life expectancy.13 This 
novel and collaborative pharmacist review service initia-
tive reported here drew on the skill sets of pharmacists 
from different sectors and was able to address the wide 
variety of residents’ pharmaceutical care needs, which 
may not have been fully within the competence of phar-
macists from a single sector. It is likely that meeting 
these pharmaceutical care needs had a positive impact 
on the health of the ID residents.
The findings of this study also highlight the anticho-
linergic burden experienced by residents, and reducing 
this burden for 30% of those residents with high anti-
cholinergic burden scores (ie, a score over 3) is another 
key outcome of the service initiative. There is increasing 
evidence of medicines with anticholinergic properties 
being associated with falls, cognitive deterioration, 
drowsiness, constipation in older people, an increased 
risk of dementia and higher mortality.20 As such, the use 
of these medicines should be limited in older people. 
There is also evidence that these medicines are more 
commonly prescribed to patients with ID and that these 
patients are more likely to be prescribed anticholin-
ergic medication to treat symptoms of antipsychotic 
agents.21–23 In this study, approximately three- quarters 
of the residents were prescribed at least one medicine 
with anticholinergic activity, of whom over a third had 
a high anticholinergic burden score. This is higher 
than or at the very highest end of recent estimates of 
20%–50% of older people in England being prescribed 
at least one medication with anticholinergic activity,20 24 
even though the average age of the residents in this study 
was only 56. Our findings therefore strongly support the 
high prevalence of anticholinergic prescribing in the ID 
population highlighted in the 2018 LeDeR report and 
confirms the need for service development initiatives 
such as is reported here to support the work of the NHS 
England STOMP programme to reduce overmedication 
in the ID population.
The interventions made by pharmacists in this study 
also addressed other priority areas of care associated 
with increased mortality and morbidity in the popula-
tion with ID, particularly respiratory care where 80% 
of residents prescribed respiratory medicines required 
interventions. It is known that people with ID have an 
increased incidence of asthma and COPD, and within 
Wirral, both diagnoses of asthma and COPD are slightly 
higher than the national average (7.6% and 2.6%, 
respectively).25 Respiratory diseases were highlighted in 
the 2018 LeDeR report as being the highest single cause 
of death (19%) in the general population with ID.26 
While we found no previous studies of respiratory care 
specific to people with ID, there is an increasing body of 
literature on pharmacists’ interventions in asthma and 
COPD management in the general population, which 
has shown benefits in terms of increased adherence to 
medicines and reductions in routine hospital visits and 
other health- related costs.27 28 Our findings suggest that 
similar findings are likely in the residential population 
with ID, but further research is warranted to confirm 
this.
In this study, the pharmacists also made interven-
tions/recommendations about constipation manage-
ment, another LeDeR priority area, for 10% of residents. 
Effective management of constipation in people with 
ID is essential as it has a higher prevalence than in the 
general population and is a common cause of prevent-
able death.3 As such, the study findings suggest that this 
should continue to be an important focus for pharma-
ceutical care reviews in the residential population with 
ID.
However, limitations of the study include that the results 
cannot necessarily be generalised across the country, 
since the study population were ID care home residents 
from a single CCG area. Additionally, the interventions 
were undertaken with restricted access to individual 
patient records. Greater access to these records may have 
changed or reduced the need for some of the recommen-
dations to GPs and psychiatrists. Finally, the study focused 
on specific concerns of medication management that are 
known and published (eg, in the LeDeR report).
The reviews conducted by the pharmacist followed a 
broad framework, focusing on national priorities. The 
reviews themselves did not exclude any area of medi-
cines optimisation and were led by the individual resi-
dent’s needs. However, the evaluation focuses on the 
extent to which this pharmacist- led initiative can impact 
on these national priorities and therefore did not 
consider the broader implications of other medicines- 
related interventions beyond reporting the number and 
nature of them. Similarly, this study focuses exclusively 
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independently and otherwise in the community. This 
reflected the current CCG priorities and highlighted 
health need, but future initiatives would benefit from 
exploring the requirements of this related population, 
as well as including them in service pathways.
Nevertheless, the data presented here do suggest 
benefit for residents with ID, and the introduction of 
Primary Care Networks in England offers an opportu-
nity for such cross- sector collaborative service models to 
be developed, which would be expected to contribute 
to workload pressure reduction for GPs, emergency 
health services and secondary care services. The find-
ings of this study suggest that commissioners should 
consider the frequency of reviews within this popula-
tion group and how to best use the available resource 
within the pharmacy profession. However, a full eval-
uation of the benefit for residents with ID and the 
wider health economy of any larger scale uptake of 
this service initiative would require an appropriately 
designed randomised controlled trial, which should 
include a health economic evaluation. This would 
likely require a prior feasibility study to identify viable 
primary and secondary outcomes to determine the 
effectiveness of the service. The economic evaluation 
should include clinical and humanistic outcomes in 
addition to economic outcomes.29 Qualitative explo-
ration of the perspectives of community pharmacists’, 
GPs’, care home staff and Specialist Mental Health 
Trust staff, among others, on the outcomes and quality 
of the service provided might also yield useful insights.
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